U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C22H31N5O4
Molecular Weight 429.5126
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of MELAGATRAN

SMILES

NC(=N)C1=CC=C(CNC(=O)[C@@H]2CCN2C(=O)[C@H](NCC(O)=O)C3CCCCC3)C=C1

InChI

InChIKey=DKWNMCUOEDMMIN-PKOBYXMFSA-N
InChI=1S/C22H31N5O4/c23-20(24)16-8-6-14(7-9-16)12-26-21(30)17-10-11-27(17)22(31)19(25-13-18(28)29)15-4-2-1-3-5-15/h6-9,15,17,19,25H,1-5,10-13H2,(H3,23,24)(H,26,30)(H,28,29)/t17-,19+/m0/s1

HIDE SMILES / InChI

Molecular Formula C22H31N5O4
Molecular Weight 429.5126
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Approval Year

Substance Class Chemical
Created
by admin
on Fri Dec 15 16:30:52 UTC 2023
Edited
by admin
on Fri Dec 15 16:30:52 UTC 2023
Record UNII
2A9QP32MD4
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
MELAGATRAN
INN   MART.   MI   WHO-DD  
INN  
Official Name English
melagatran [INN]
Common Name English
Glycine, N-[(1R)-2-[(2S)-2-[[[[4-(aminoiminomethyl)phenyl]methyl]amino]carbonyl]-1-azetidinyl]-1-cyclohexyl-2-oxoethyl]-
Systematic Name English
Melagatran [WHO-DD]
Common Name English
MELAGATRAN [MART.]
Common Name English
MELAGATRAN [MI]
Common Name English
N-[(1R)-2-[(2S)-2-[[[[4-(Aminoiminomethyl)phenyl]methyl]amino]carbonyl]-1-azetidinyl]-1-cyclohexyl-2-oxoethyl]glycine
Systematic Name English
Classification Tree Code System Code
WHO-ATC B01AE04
Created by admin on Fri Dec 15 16:30:52 UTC 2023 , Edited by admin on Fri Dec 15 16:30:52 UTC 2023
WHO-VATC QB01AE04
Created by admin on Fri Dec 15 16:30:52 UTC 2023 , Edited by admin on Fri Dec 15 16:30:52 UTC 2023
NCI_THESAURUS C263
Created by admin on Fri Dec 15 16:30:52 UTC 2023 , Edited by admin on Fri Dec 15 16:30:52 UTC 2023
Code System Code Type Description
DRUG BANK
DB13616
Created by admin on Fri Dec 15 16:30:52 UTC 2023 , Edited by admin on Fri Dec 15 16:30:52 UTC 2023
PRIMARY
MERCK INDEX
m7149
Created by admin on Fri Dec 15 16:30:52 UTC 2023 , Edited by admin on Fri Dec 15 16:30:52 UTC 2023
PRIMARY Merck Index
CHEBI
43966
Created by admin on Fri Dec 15 16:30:52 UTC 2023 , Edited by admin on Fri Dec 15 16:30:52 UTC 2023
PRIMARY
CAS
159776-70-2
Created by admin on Fri Dec 15 16:30:52 UTC 2023 , Edited by admin on Fri Dec 15 16:30:52 UTC 2023
PRIMARY
NCI_THESAURUS
C66077
Created by admin on Fri Dec 15 16:30:52 UTC 2023 , Edited by admin on Fri Dec 15 16:30:52 UTC 2023
PRIMARY
EPA CompTox
DTXSID30166724
Created by admin on Fri Dec 15 16:30:52 UTC 2023 , Edited by admin on Fri Dec 15 16:30:52 UTC 2023
PRIMARY
SMS_ID
100000081464
Created by admin on Fri Dec 15 16:30:52 UTC 2023 , Edited by admin on Fri Dec 15 16:30:52 UTC 2023
PRIMARY
ChEMBL
CHEMBL266349
Created by admin on Fri Dec 15 16:30:52 UTC 2023 , Edited by admin on Fri Dec 15 16:30:52 UTC 2023
PRIMARY
INN
7414
Created by admin on Fri Dec 15 16:30:52 UTC 2023 , Edited by admin on Fri Dec 15 16:30:52 UTC 2023
PRIMARY
MESH
C109573
Created by admin on Fri Dec 15 16:30:52 UTC 2023 , Edited by admin on Fri Dec 15 16:30:52 UTC 2023
PRIMARY
EVMPD
SUB08718MIG
Created by admin on Fri Dec 15 16:30:52 UTC 2023 , Edited by admin on Fri Dec 15 16:30:52 UTC 2023
PRIMARY
FDA UNII
2A9QP32MD4
Created by admin on Fri Dec 15 16:30:52 UTC 2023 , Edited by admin on Fri Dec 15 16:30:52 UTC 2023
PRIMARY
PUBCHEM
183797
Created by admin on Fri Dec 15 16:30:52 UTC 2023 , Edited by admin on Fri Dec 15 16:30:52 UTC 2023
PRIMARY
Related Record Type Details
BINDER->LIGAND
Of the human subjects, one male and one female had essentially no plasma protein binding of melagatran, whereas the other two had values of 13.3 and 15.3%.
BINDING
TARGET -> INHIBITOR
Ki
SALT/SOLVATE -> PARENT
SOLVATE->ANHYDROUS
Related Record Type Details
PRODRUG -> METABOLITE ACTIVE
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
ORAL BIOAVAILABILITY PHARMACOKINETIC